Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 9/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.37 |
| ▸ | PIK3CD | O00329 | 6/20 | 0.37 |
| ▸ | PIK3R2 | O00459 | 5/20 | 0.37 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6071514 | 0.68 | IKBKB (0.47) | IKBKBPIK3CDPIK3R2CHUK | |
| SCHEMBL14028277 | 0.67 | IKBKB (0.94) | IKBKBCHUK | |
| SCHEMBL6071879 | 0.66 | KDM4E (0.39) | PIK3CD | |
| SCHEMBL31648194 | 0.66 | HTR2C (0.54) | — | |
| SCHEMBL22721015 | 0.66 | HTR2C (0.54) | — | |
| SCHEMBL6072086 | 0.65 | IDO1 (0.43) | — | |
| SCHEMBL6071637 | 0.65 | ALDH1A1 (0.39) | PIK3CD | |
| SCHEMBL6071420 | 0.65 | KDM4E (0.39) | — | |
| SCHEMBL6072026 | 0.65 | IKBKB (0.51) | IKBKBPIK3CDPIK3R2CHUK | |
| SCHEMBL23323600 | 0.64 | HCRTR2 (0.43) | IKBKBTAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | WYETH (US) | 2006-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060264460-A1 | 3-Cyanoquinoline inhibitors of Tpl2 kinase and methods of making and using the same | TNNI3K, CSNK1A1L, CDKL1 | IKBKB 603/4885TAAR1 1996/4885PIK3CD 814/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.